AMGEN Inc.

NASDAQ:AMGN

241.75

+0.25 (+0.10%)

7:59:12 PM EDT: $241.85 +0.10 (+0.04%)

Products

Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With Kras G12c Mutation

Published: 12/16/2020 21:45 GMT

AMGEN Inc. (AMGN) - Amgen Submits Sotorasib New Drug Application to U.S. FDA for Advanced Or Metastatic Non-small Cell Lung Cancer With Kras G12c Mutation.
Amgen Inc - FDA Granted Breakthrough Therapy Designation for Sotorasib.
Amgen Inc - Sotorasib Application Being Reviewed Under FDA Real-time Oncology Review (rtor) Pilot Program.